NEW YORK (GenomeWeb) – Most of the approximately 300 public comments that the Centers for Medicare & Medicaid Services has gotten for its draft national coverage determination (NCD) for next-generation sequencing cancer panels criticize it for being too restrictive.

A perspective that hasn't gotten as much attention is that the CMS draft coverage decision is perhaps not restrictive enough, and that the policy could be bad for patients by increasing off-label drug use based on the results of NGS panels.